Español 
English
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS
Artículos Relacionados
-
UDIBI
Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región....
-
UDIBI
Validation of a cell-based colorimetric reporter gene assay for the evaluation of Type I Interferons. VER MÁS
-
-
UDIBI
Colloids and Surfaces A: Physicochemical and Engineering Aspects. Structural and physicochemical characteristics of one-step PAMAM dendrimeric nanoparticles. VER MÁS
-
-
UDIBI
Fecha de publicación: 8 noviembre 22 Altered neutrophil-to-lymphocyte ratio in sepsis secondary to canine parvoviral enteritis treated with and...
-
UDIBI
CD80 Expression Correlates with IL-6 Production in THP-1-Like Macrophages Costimulated with LPS and Dialyzable Leukocyte Extract (Transferon®). VER MÁS
-
UDIBI
Fecha de publicación: Enero 2019Valproic acid promotes a decrease in mycobacterial survival by enhancing nitric oxide production in macrophages...
